With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

The Pandemic Started 5 Years Ago — Here Are 36 Things That Happened Back Then That Will Make You Question Reality Well, well, ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an agreement to acquire Chimerix CMRX. Meanwhile, other pi ...

Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...

FDA nominee Marty Makary pledges to review the cancellation of a key flu vaccine meeting, addressing concerns over ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.